MedTrace Logo

Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)

NCT06696131 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-04-30

No results posted yet for this study

Summary

The overall purpose of this study is to look at the safety and effectiveness of administering Tenecteplase (TNK) into the brain bleed (hematoma) instead of another clot-dissolving drug known as recombinant tissue plasminogen activator (rtPA), which is the current standard practice. Clot dissolving (Fibrinolytic) drugs work to break down blood clots and have been found to improve health outcomes when applied directly into the hematoma within the brain. Patients who take part in this study will undergo the same surgical procedure that would normally be performed to treat them, but with the exception of TNK not rtPA.

Conditions

  • Intracerebral Hemorrhage
  • Intracranial Hemorrhages
  • Hemorrhagic Strokes

Interventions

DRUG

TNK

TNK will be delivered into the site of the intracerebral hemorrhage via a brain catheter.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Gaurav Gupta, MD

    lead OTHER

Principal Investigators

  • Gaurav Gupta, MD · Rutgers University, RWJ Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-15
Primary Completion
2028-01-15
Completion
2028-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06696131 on ClinicalTrials.gov